Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

The 5q- syndrome: biology and treatment.

Padron E, Komrokji R, List AF.

Curr Treat Options Oncol. 2011 Dec;12(4):354-68. doi: 10.1007/s11864-011-0165-1.

PMID:
21964863
2.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.

Nomdedeu M, Maffioli M, Calvo X, Martínez-Trillos A, Baumann T, Díaz-Beyá M, Aguilar JL, Rozman M, Costa D, Esteve J, Cervantes F, Colomer D, Nomdedeu B.

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20. No abstract available.

PMID:
21764129
3.

Role of lenalidomide in the treatment of myelodysplastic syndromes.

Komrokji RS, List AF.

Semin Oncol. 2011 Oct;38(5):648-57. doi: 10.1053/j.seminoncol.2011.04.015. Review.

PMID:
21943671
5.

Biology and treatment of the 5q- syndrome.

Padron E, Komrokji R, List AF.

Expert Rev Hematol. 2011 Feb;4(1):61-9. doi: 10.1586/ehm.11.2. Review.

PMID:
21322779
6.

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.

Voutsadakis IA, Cairoli A.

Leuk Lymphoma. 2012 May;53(5):779-88. doi: 10.3109/10428194.2011.623255. Epub 2011 Nov 25. Review.

PMID:
21955212
7.

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

Jonasova A, Bokorova R, Polak J, Vostry M, Kostecka A, Hajkova H, Neuwirtova R, Siskova M, Sponerova D, Cermak J, Mikulenkova D, Cervinek L, Brezinova J, Michalova K, Fuchs O.

Eur J Haematol. 2015 Jul;95(1):27-34. doi: 10.1111/ejh.12457. Epub 2014 Oct 31.

PMID:
25284710
8.

Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.

Aschauer G, Greil R, Linkesch W, Nösslinger T, Stauder R, Burgstaller S, Fiegl M, Fridrik M, Girschikofsky M, Keil F, Petzer A.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5.

PMID:
26422252
9.

Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

Nimer SD.

J Clin Oncol. 2006 Jun 1;24(16):2576-82. Review.

PMID:
16735711
10.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Kelaidi C, Eclache V, Fenaux P.

Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Review.

PMID:
18217896
11.
12.

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

List AF, Baker AF, Green S, Bellamy W.

Cancer Control. 2006 Dec;13 Suppl:4-11. Review.

13.

Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K.

Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.

PMID:
22172461
14.

Lenalidomide for treatment of myelodysplastic syndromes.

Komrokji RS, List AF.

Curr Pharm Des. 2012;18(22):3198-203. Review.

PMID:
22571699
15.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28.

PMID:
21715006
16.

Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.

Revicki DA, Brandenburg NA, Muus P, Yu R, Knight R, Fenaux P.

Leuk Res. 2013 Mar;37(3):259-65. doi: 10.1016/j.leukres.2012.11.017. Epub 2012 Dec 27.

PMID:
23273538
17.

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.

Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M, Ozawa K.

Int J Hematol. 2009 Oct;90(3):353-60. doi: 10.1007/s12185-009-0400-8. Epub 2009 Aug 25.

PMID:
19705057
18.

Lenalidomide in del 5q MDS: responses and side effects revisited.

Tiu RV, Sekeres MA.

Leuk Res. 2011 Nov;35(11):1440-1. doi: 10.1016/j.leukres.2011.06.031. Epub 2011 Jul 20. No abstract available.

PMID:
21764127
19.

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; Groupe Francophone des Myélodysplasies..

Br J Haematol. 2012 Mar;156(5):619-25. doi: 10.1111/j.1365-2141.2011.08979.x. Epub 2011 Dec 23.

PMID:
22211483
20.

[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].

Katayama Y.

Rinsho Ketsueki. 2011 Jul;52(7):447-51. Review. Japanese. No abstract available.

PMID:
21821975

Supplemental Content

Support Center